Proactive Investors - Run By Investors For Investors

AstraZeneca wins regulatory approval for Europe's first type-1 diabetes drug taken by mouth

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism
diabetes on a dial
Type-1 diabetes is a chronic disease where the pancreas produces little or no insulin

AstraZeneca PLC (LON:AZN) has won regulatory approval for a breakthrough diabetes drug with its new product Forxiga becoming the first oral treatment for the type-1 form of the disease in Europe.

It will be used as an “adjunct” to insulin for people whose glucose levels are not adequately controlled with the hormone alone.

“We look forward to bringing Forxiga to a patient population that has not had any approved oral medicines available before," said Elisabeth Björk, AZ’s head of cardiovascular, renal and metabolism.

It is estimated that there are just over 300,000 UK sufferers of type-1 diabetes, a chronic disease that means pancreas produces little or no insulin.

The condition is caused by an autoimmune reaction that destroys the beta cells in the pancreas, which make insulin.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

Challenge trials can speed up vaccine development
May 30 2019
The challenge trial charts the entire disease life cycle from healthy to sick and back to health.
doctor
Tue
Oncimmune is a specialist in the field of immunodiagnostics
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use